http://www.pharmexec.com/pharmexec/Popular+Articles/Article/list/48159 The publisher of Pharmaceutical Executive brings visitors PharmExec.com, which serves up a daily dose of news and features from the world of pharma business and marketing. 2013-06-20T07:03:53Z http://www.pharmexec.com/pharmexec/Strategy/Off-the-Hook-Pharm-Execs-Annual-Press-Audit/ArticleStandard/Article/detail/764160?contextCategoryId=48159&ref=25 Our annual press audit finds that the big news in 2011 for pharma was ... no news. 2012-03-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/102012/764160/pharma_&_press_120_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Noteworthy/Does-Your-Portfolio-Review-Reflect-What-the-Patien/ArticleStandard/Article/detail/766122?contextCategoryId=48159&ref=25 The quest for 'radical' R&D innovation is often pursued at the expense of treatments with hidden blockbuster potential, writes Bert Spilker. 2012-03-27T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/132012/766122/bert_Spilker_120_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/132012/766122/bert.s2_flash.jpg HTML http://www.pharmexec.com/pharmexec/Noteworthy/Only-Connect-Finding-the-Key-to-Digital-Marketing/ArticleStandard/Article/detail/763590?contextCategoryId=48159&ref=25 Jim Currie and Baber Ghauri talk to Pharm Exec about making connections that resonate with audiences in a digital world. 2012-03-07T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/102012/763590/Digital_technology_120_thumbnail.jpg HTML http://www.pharmexec.com/pharmexec/Professional+Marketing/Innovation-Why-is-Pharma-Scared-to-Death/ArticleStandard/Article/detail/755086?contextCategoryId=48159&ref=25 It's a disturbing irony: In an industry whose entire economic value is founded on its ability to innovate, why is there so much discomfort with the risk required for innovation. Where did the courage to innovate go? 2012-01-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012012/755086/anxiety2_flash.jpg XML http://www.pharmexec.com/pharmexec/Back+Page/Top-Medical-Innovations-2012/ArticleStandard/Article/detail/755083?contextCategoryId=48159&ref=25 A selection of the recent breakthrough technologies showcased at the Cleveland Clinic's Medical Innovations Summit. 2012-01-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012012/755083/medical-small_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012012/755083null XML http://www.pharmexec.com/pharmexec/Global/Pharma-2012-Hard-Times-Before-the-Harvest/ArticleStandard/Article/detail/755087?contextCategoryId=48159&ref=25 The challenge for 2012 is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap. 2012-01-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012012/755087/Harvest-small_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Technology/iPad-Apps-Are-You-Content-with-your-Content/ArticleStandard/Article/detail/755081?contextCategoryId=48159&ref=25 Pharma has become unusually quick to strike embrace the iPad. But the industry's inherent conservatism means it has some way to go to fully milk the device's potential. 2012-01-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012012/755081/ipad-small_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012012/755081/ipad-small_flash.jpg XML http://www.pharmexec.com/pharmexec/Deals/Pharm-Execs-2012-Pipeline-Report/ArticleStandard/Article/detail/752361?contextCategoryId=48159&ref=25 It's a neck and neck race toward safer, faster, and medically superior treatments. Which organizations have what it takes to jockey their products into the winner's circle? 2011-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512011/752361/pipeline-small_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Global+Report/Should-the-US-Gamble-with-Risk-Sharing/ArticleStandard/Article/detail/739261?contextCategoryId=48159&ref=25 Especially when payers come to the table holding the best cards — leaving industry second-guessing its strategy. 2011-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372011/739261/casino-chips.crop_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Technology/Pharma-and-Social-Media-Ready-to-Make-Nice/ArticleStandard/Article/detail/739276?contextCategoryId=48159&ref=25 The time is right for industry to overcome its social media phobia once and for all. 2011-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372011/739276/social-media_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372011/739276null XML http://www.pharmexec.com/pharmexec/From+the+Editor/Get-Back-in-the-Box/ArticleStandard/Article/detail/739272?contextCategoryId=48159&ref=25 Despite the gloom, most forecasts show the US will stay atop the industry in profits for at least the next generation of products. 2011-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372011/739272null XML http://www.pharmexec.com/pharmexec/Noteworthy/Precious-Mettle/ArticleStandard/Article/detail/730198?contextCategoryId=48159&ref=25 Taking Onyx Pharmaceuticals to new heights – CEO Tony Coles talks to PharmExec about the midsize company's transition from adolescence to adulthood. 2011-07-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/282011/730198/Tony-Coles_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Global+Report/What-the-2011-Census-of-India-Reveals-for-Pharma/ArticleStandard/Article/detail/730201?contextCategoryId=48159&ref=25 What India's latest census tells us about current and future pharma opportunities. 2011-07-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/282011/730201/India-flag_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/282011/730201null XML http://www.pharmexec.com/pharmexec/Back+Page/How-to-Prevent-a-Facebook-Faux-Pas/ArticleStandard/Article/detail/730202?contextCategoryId=48159&ref=25 'Like' and 'Dislike' practices in the virtual Facebook pharmaceutical world. 2011-07-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/282011/730202/0_61_hand_over_mouth_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/282011/730202null XML http://www.pharmexec.com/pharmexec/Professional+Marketing/10-Emergency-Brand-Building-Questions/ArticleStandard/Article/detail/730207?contextCategoryId=48159&ref=25 EAB Member Al Topin delivers 10 questions that should drive your brand-building marketing program. 2011-07-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/282011/730207/Glass_116358957_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/282011/730207null XML http://www.pharmexec.com/pharmexec/Global+Report/12th-Annual-Pharm-Exec-50/ArticleStandard/Article/detail/719596?contextCategoryId=48159&ref=25 Who's taken this year's top spot? Find out in Pharm Exec's annual run-down of the world's Top 50 pharma companies. 2011-05-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/192011/719596/phara50-cropped_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/192011/719596/phara50_flash.jpg XML http://www.pharmexec.com/pharmexec/Back+Page/On-Tour-with-Mercks-Robots/ArticleStandard/Article/detail/719602?contextCategoryId=48159&ref=25 A factory tour to examine Merck's automated robots—and the human minds that inspire them 2011-05-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/192011/719602/Merck_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/192011/719602null XML http://www.pharmexec.com/pharmexec/Commentary/UK-Stakeholders-Have-Their-Say-on-Value-Based-Pric/ArticleStandard/Article/detail/719595?contextCategoryId=48159&ref=25 The UK coalition government's consultation on the intro of value-based pricing has invited caution and resistance 2011-05-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/192011/719595null XML http://www.pharmexec.com/pharmexec/Professional+Marketing/Blame-the-Driver-Not-the-Car/ArticleStandard/Article/detail/719594?contextCategoryId=48159&ref=25 Why is building a successful marketing program so difficult? It should be simple, if your product is worth marketing. 2011-05-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/192011/719594/Driving1_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/192011/719594null XML http://www.pharmexec.com/pharmexec/Washington+Report/Outrage-Over-Drug-Prices/ArticleStandard/Article/detail/719622?contextCategoryId=48159&ref=25 Stiff price tags draw scrutiny from Congress and consumers, and raise questions about FDA policies 2011-05-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/192011/719622null XML http://www.pharmexec.com/pharmexec/Noteworthy/The-Brand-Promotion-Gauntlet/ArticleStandard/Article/detail/711577?contextCategoryId=48159&ref=25 When dealing with the pharmaceutical marketplace, why is keeping things simple so complex? 2011-03-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/112011/711577/army-gun_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/112011/711577null XML http://www.pharmexec.com/pharmexec/From+the+Editor/Making-Sense-of-Market-Chaos/ArticleStandard/Article/detail/711569?contextCategoryId=48159&ref=25 Pharma can be an insular industry, with limited capacity to gaze beyond its own narrow frame of vision 2011-03-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/112011/711569null XML http://www.pharmexec.com/pharmexec/Noteworthy/Where-have-all-the-Scientists-Gone/ArticleStandard/Article/detail/711578?contextCategoryId=48159&ref=25 With an emphasis on short-term objectives rather than long-term goals, pharma is missing a huge opportunity in applying market science to drive adherence 2011-03-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/112011/711578null XML http://www.pharmexec.com/pharmexec/Noteworthy/John-Castellani-Industrys-Level-Bet-on-a-Dizzying-/ArticleStandard/Article/detail/711574?contextCategoryId=48159&ref=25 Can PhRMA's own business model synch with industry's Pharm Exec takes a closer look at PhRMA's new leadership. 2011-03-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/112011/711574/Castellani_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/112011/711574null XML http://www.pharmexec.com/pharmexec/Noteworthy/Skipping-the-Needle-Pharm-Execs-Brand-of-the-Year/ArticleStandard/Article/detail/707511?contextCategoryId=48159&ref=25 Novartis' Gilenya is a step forward in treating Multiple Sclerosis. But generating increased compliance is another story 2011-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/072011/707511/gramaphone_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/072011/707511null XML http://www.pharmexec.com/pharmexec/Global+Report/Growing-Stronger-After-the-Storm/ArticleStandard/Article/detail/707510?contextCategoryId=48159&ref=25 To manage through a resource-constrained environment, it is essential to get the most out of procurement planning 2011-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/072011/707510/cloud2_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/072011/707510null XML http://www.pharmexec.com/pharmexec/Popular+Articles/Key-Strategies-for-Planning-and-Executing-Successf/ArticleStandard/Article/detail/636935?contextCategoryId=48159&ref=25 The most imporant thing to remember when planning a global clinical trial is very basic and almost always overlooked 2009-10-03T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/442009/636935null XML http://www.pharmexec.com/pharmexec/Popular+Articles/The-Difficult-Art-of-Budgeting-for-Translation/ArticleStandard/Article/detail/636934?contextCategoryId=48159&ref=25 What you need to know in order to budget right and for less money 2009-10-03T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/442009/636934null XML http://www.pharmexec.com/pharmexec/Noteworthy/Whats-the-Deal-at-Solvay/ArticleStandard/Article/detail/616637?contextCategoryId=48159&ref=25 The Belgian drugmaker is pursuing a sale, inking deals, issuing debt, and launching a power drug for Parkinson's—all at once. 2009-08-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/322009/616637/PE0809_solvay_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/322009/616637null XML http://www.pharmexec.com/pharmexec/Noteworthy/Betting-the-Pharma/ArticleStandard/Article/detail/616636?contextCategoryId=48159&ref=25 With the biotech industry reeling from the recession, big drugmakers hold all the cards when it comes to making deals, but picking a winner is still a gamble. Here are 10 to place stakes on. 2009-08-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/322009/616636/PE0809_M&A_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/322009/616636null XML http://www.pharmexec.com/pharmexec/Noteworthy/Ive-Seen-The-Revolution-and-Its-Not-Working/ArticleStandard/Article/detail/605654?contextCategoryId=48159&ref=25 Agency Insider Mark Chattaway infiltrates the world of online social media. His consensus: Advertising on social networks is iffy at best 2009-07-07T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/262009/605654/AgencyImageTwo_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/262009/605654null XML http://www.pharmexec.com/pharmexec/Noteworthy/French-Revolution/ArticleStandard/Article/detail/608966?contextCategoryId=48159&ref=25 Chris Viehbacher's first fast and furious six months at the top of Sanofi-Aventis have heads spinning...and rolling. 2009-07-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/282009/608966/PE0709_viebacher_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/282009/608966null XML http://www.pharmexec.com/pharmexec/Popular+Articles/Agency-Confidential-The-Scoopmdash-What-Your-Agenc/ArticleStandard/Article/detail/605663?contextCategoryId=48159&ref=25 Pharma friendless on Facebook | DTC ad spending flat | Rate of healthcare marketing and advertising falls | Consumers chose food over meds | Some see light at tunnel's end 2009-06-03T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/262009/605663null XML http://www.pharmexec.com/pharmexec/News+Analysis/US-Pharma-Market-To-Decline-in-2009/ArticleStandard/Article/detail/594628?contextCategoryId=48159&ref=25 IMS has revised its 2009, forecast and the outlook isn't pretty for the United States, which looks to drop 1 to 2 percent in the coming year. 2009-04-22T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/172009/594628null HTML http://www.pharmexec.com/pharmexec/Web+Exclusives/The-Battle-for-Oncology-KOLs/ArticleStandard/Article/detail/594632?contextCategoryId=48159&ref=25 Companies are fighting for strong relationships with key opinion leaders—and Genentech is winning, hands down. 2009-04-22T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/172009/594632null HTML http://www.pharmexec.com/pharmexec/Strategy/JampJ-Eliminates-900-Sales-Positions/ArticleStandard/Article/detail/593480?contextCategoryId=48159&ref=25 In an effort to realign its sales division to reflect the current pharma environment—smaller, faster, better—Johnson & Johnson is trimming its sales force. 2009-04-15T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/162009/593480null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Pharma-Companies-Hit-With-Warnings-for-Search-Mark/ArticleStandard/Article/detail/592363?contextCategoryId=48159&ref=25 FDA is cracking down on content in search engine advertisements. The argument is that there is a serious deficiency of risk information in the tiny link ads that appear on search ads. With pharma already wary of marketing online, will FDA’s tactic hurt future Web campaigns? 2009-04-08T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/152009/592363null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Pfizer-Begins-Wyeth-Integration-with-New-Research-/ArticleStandard/Article/detail/592362?contextCategoryId=48159&ref=25 Just two months after the purchase of Wyeth, Pfizer breaks its research division into two—one for large molecules and vaccines, and another for small molecules—with Wyeth and Pfizer execs at the helms. 2009-04-08T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/152009/592362null HTML http://www.pharmexec.com/pharmexec/Sales/Goodbye-Willy-Loman/ArticleStandard/Article/detail/591827?contextCategoryId=48159&ref=25 The days of pharma sales reps going office-to-office with samples and brochures are done. These days, they need to turn their attention to payers, pharmacists, and consumers 2009-04-06T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/152009/591827null HTML http://www.pharmexec.com/pharmexec/Strategy+Articles/Deborah-Dunsire-Woman-of-the-Year/ArticleStandard/Article/detail/592058?contextCategoryId=48159&ref=25 From her start as a physician working in apartheid-era South Africa to the dramatic turnaround and takeover of Millennium, Deborah Dunsire has lived a life that has defied all expectations. 2009-04-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/152009/592058/PE0409_woty_flash.jpg XML http://www.pharmexec.com/pharmexec/Sales+Articles/The-New-Sales-Force/ArticleStandard/Article/detail/585604?contextCategoryId=48159&ref=25 The arms race is over, and it's time to reinvent pharma sales. Here's what forward-looking companies are experimenting with—and how it's working 2009-03-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/102009/585604null XML